EATONTOWN, N.J., July 18 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Nasdaq: RPCX) announced today the election of John T.
Spitznagel to Roberts Board of Directors.   Mr. Spitznagel joined the
Company earlier this year to fill the then newly created position of
Executive Vice President, Worldwide Sales and Marketing.
    Prior to joining Roberts, Mr. Spitznagel held the position of
President of Reed and Carnrick Pharmaceuticals, a division of Block Drug.
He also served as Senior Vice President, Marketing and Sales at Wyeth
Laboratories, a division of American Home Products, and as Product
Marketing Director at Roche.  He holds an MBA in marketing (Magna Cum
Laude) from Fairleigh-Dickinson Graduate School of Business
Administration, Rutherford, N.J.
    Commenting on the announcement, Dr. Robert A. Vukovich, President and
CEO of Roberts, said  "John has a wealth of experience in pharmaceutical
sales and marketing.  We are enthusiastic about the talents he has brought
to Roberts in support of our portfolio of licensed and acquired products
such as Noroxin for the U.S. market and Eminase with its global potential.
Moreover, Roberts recently received an FDA approvable letter for its first
internally developed drug, ProAmatine(TM) , and we are optimistic about
the potential near-term FDA approval of our second pipeline product,
Agrelin(R).  We are fortunate to have John on board as the Company looks
forward to this new and exciting phase in its growth cycle, the
commercialization of its proprietary pharmaceutical pipeline".
    Roberts Pharmaceutical Corporation is an international pharmaceutical
company focusing on the acquisition and development of late-stage drugs.
Roberts currently markets its products in seven countries and has
operating subsidiaries in the U.S., Canada, and the United Kingdom.
Roberts was recently listed in the Fortune Top 50 Fastest Growing
Companies, the Inc. Magazine Top 100 Listing of Fastest Growing Companies,
as well as by CEO Magazine's Top 50 Companies.
    This release contains forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action and competing
products. Any changes in such assumptions or external factors could
produce significantly different results.